UBS Group
APTO

UBS Group’s Aptose Biosciences, Inc. APTO Stock Holding History

UBS Group’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,928
Closed -$13K – 11071
2024
Q4 		$13K Sell
1,928
-2,521
-57% -$23K ﹤0.01% 8169
2024
Q3 		$54.9K Buy
+4,449
New +$67.8K ﹤0.01% 6759
2024
Q1 		– Sell
-253
Closed -$19.3K – 10454
2023
Q4 		$19.3K Buy
+253
New +$19.6K ﹤0.01% 7125
2023
Q3 		– Sell
-1
Closed -$118 – 9246
2023
Q2 		$125 Sell
1
-8
-89% -$1.66K ﹤0.01% 8474
2023
Q1 		$2.64K Buy
+9
New +$2.61K ﹤0.01% 8473
2022
Q4 		– Hold
0
– – – 10670
2022
Q3 		– Hold
0
– – – 11396
2022
Q2 		– Sell
-3
Closed -$1.44K – 11384
2022
Q1 		$2K Sell
3
-76
-96% -$42K ﹤0.01% 9755
2021
Q4 		$48K Buy
79
+38
+93% +$35.7K ﹤0.01% 6953
2021
Q3 		$40K Buy
41
+21
+105% +$26.3K ﹤0.01% 6527
2021
Q2 		$30K Buy
20
+16
+400% +$34.9K ﹤0.01% 6952
2021
Q1 		$10K Sell
4
-3
-43% -$5.95K ﹤0.01% 7954
2020
Q4 		$14K Buy
+7
New +$16.4K ﹤0.01% 7241
2020
Q3 		– Sell
-3
Closed -$8K – 8588
2020
Q2 		$8K Buy
+3
New +$9.68K ﹤0.01% 7171
2019
Q4 		– Sell
-12
Closed -$11K – 8529
2019
Q3 		$11K Buy
12
+5
+71% +$5.69K ﹤0.01% 7128
2019
Q2 		$8K Buy
7
+6
+600% +$5.52K ﹤0.01% 7213
2019
Q1 		$1K Sell
1
-24
-96% -$21.7K ﹤0.01% 7589
2018
Q4 		$22K Buy
+25
New +$24.6K ﹤0.01% 6718
2018
Q3 		– Sell
-7
Closed -$13K – 8373
2018
Q2 		$13K Buy
7
+2
+40% +$3.19K ﹤0.01% 7005
2018
Q1 		$7K Sell
5
-4
-44% -$5.35K ﹤0.01% 7099
2017
Q4 		$10K Buy
9
+4
+80% +$3.09K ﹤0.01% 7042
2017
Q3 		$3K Buy
5
+2
+67% +$1.34K ﹤0.01% 7417
2017
Q2 		$1K Hold
3
– – ﹤0.01% 7538
2017
Q1 		$2K Hold
3
– – ﹤0.01% 7322
2016
Q4 		$2K Hold
3
– – ﹤0.01% 7539
2016
Q3 		$3K Buy
+3
New +$3.12K ﹤0.01% 7321
2016
Q2 		– Sell
-6
Closed -$8K – 8050
2016
Q1 		$8K Buy
6
+5
+500% +$5.96K ﹤0.01% 6804
2015
Q4 		$1K Buy
+1
New +$1.77K ﹤0.01% 8193
2015
Q1 		– Sell
-8
Closed -$23K – 9548
2014
Q4 		$23K Buy
+8
New +$24.1K ﹤0.01% 7457

Other funds holding APTO

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

UBS Group's APTO Position: Q1 2025 in Review

UBS Group sold out of Aptose Biosciences, Inc. (APTO) in Q1 2025, closing a stake of 1,928 shares — an estimated $13K sold.

UBS Group first reported a position in APTO in Q4 2014 and held it in 27 quarters. The position peaked at $54.9K in Q3 2024. 16 funds tracked by Wall St. Rank hold APTO as of Q1 2025.

  • UBS Group reported no remaining Aptose Biosciences, Inc. position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 1,928 Aptose Biosciences, Inc. shares in Q1 2025, an estimated $13K.
  • UBS Group first reported a position in Aptose Biosciences, Inc. in Q4 2014 and held it in 27 quarters.
  • UBS Group's Aptose Biosciences, Inc. position peaked at $54.9K in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.